- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib 中文名稱:巴拉塞替
Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) 是一種高度選擇性的Aurora B抑制劑,無細胞試驗中IC50為0.37 nM,作用于Aurora B比作用于Aurora A選擇性高3700倍左右。
Barasertib (AZD1152-HQPA) Chemical Structure
CAS: 722544-51-6
相關(guān)靶點 | Aurora A Aurora B Aurora C Aurora B | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | Alisertib (MLN8237) Tozasertib (VX-680) ZM 447439 MLN8054 Hesperadin Danusertib (PHA-739358) MK-5108 TCS7010 (Aurora A Inhibitor I) AMG-900 PHA-680632 SNS-314 CCT137690 GSK1070916 CYC116 TAK-901 CCT129202 SNS-314 Mesylate LY3295668 SP-96 | 點擊展開 |
相關(guān)化合物庫 | 激酶抑制劑庫 PI3K/Akt 抑制劑庫 MAPK抑制劑庫 DNA損傷/ DNA修復化合物庫 細胞周期化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
BT474 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=8 nM | 20175926 |
MDA-MB-231 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=105 nM | 20175926 |
MDA-MB-468 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=14 nM | 20175926 |
MDA-MB-435 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=125 nM | 20175926 |
L450 | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
HDLM-2 | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
KM-H2 | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
L428 | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
Daudi? | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
Raji | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
Ramos | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
BJAJ | Apoptosis Assay | 500 nM | 0-72 h | induces apoptosis in a time-dependent manner | 21371446 |
L450 | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth | 21371446 |
HDLM-2 | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth | 21371446 |
KM-H2 | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth | 21371446 |
L428 | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth | 21371446 |
Daudi? | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth significantly | 21371446 |
Raji | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth significantly | 21371446 |
Ramos | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth significantly | 21371446 |
BJAJ | Growth Inhibition Assay | 500 nM | 0-72 h | inhibits cell growth significantly | 21371446 |
L540 | Function Assay | 500 nM | 0-72 h | inhibits Aurora B kinase | 21371446 |
Daudi? | Function Assay | 500 nM | 0-72 h | inhibits Aurora B kinase | 21371446 |
Ramos | Function Assay | 500 nM | 0-72 h | inhibits Aurora B kinase | 21371446 |
LNCaP | Function Assay | 50 nM | 48 h | induces micronuclei with aneugenic mechanism | 25277659 |
LNCaP | Apoptosis Assay | 0-500 nM | 48?h | induces apoptotic cell death through caspase-3 upregulation | 25277659 |
LNCaP | Growth Inhibition Assay | 0-500 nM | 48?h | IC50=25 nM | 25277659 |
MDA-MB-361 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=70 nM | 20175926 |
HER18 | Growth Inhibition Assay | 0-10000 nM | 2-5 d | IC50=20 nM | 20175926 |
HER18 | Apoptosis Assay | 100 nM | 0/24/48 h | induces apoptosis and reduces clonogenic potential | 20175926 |
MDA-MB-231 | Apoptosis Assay | 105 nM | 0/24/48 h | induces apoptosis and reduces clonogenic potential | 20175926 |
JHH-1 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=17.4±1.0 nM | 19913935 |
JHH-2 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=218.0±10.8 nM | 19913935 |
JHH-4 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=155.6±16.8 nM | 19913935 |
HuH-1 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=27.3±5.0 nM | 19913935 |
HuH-6 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=3.7±0.6 nM | 19913935 |
HuH-7 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=6.8±0.3 nM | 19913935 |
HLE | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=45.9±6.4 nM | 19913935 |
HLF | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=126.1±12.2 nM | 19913935 |
PLC/PRF/5 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=76.9±9.9 nM | 19913935 |
SK-Hep1 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=21.9±1.2 nM | 19913935 |
Hep3B | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=7.6±1.2 nM | 19913935 |
HepG2 | Growth Inhibition Assay | 0.3–1000?nM | 72 h | EC50=14.7±1.7 nM | 19913935 |
Ramos | Apoptosis Assay | 25/50/100 nM | 48 h | increases the levels of the cleaved forms of PARP and caspase 3 | 19823168 |
Daudi? | Apoptosis Assay | 25/50/100 nM | 48 h | increases the levels of the cleaved forms of PARP and caspase 3 | 19823168 |
BALM-14 | Apoptosis Assay | 12.5/25/50 nM | 48 h | increases the levels of the cleaved forms of PARP and caspase 3 | 19823168 |
BALM-27 | Apoptosis Assay | 12.5/25/50 nM | 48 h | increases the levels of the cleaved forms of PARP and caspase 3 | 19823168 |
NB4 | Growth Inhibition Assay | 0.01/0.1/1 μM | 48 h | inhibits cell growth significantly | 18367484 |
HeLa | Function Assay | 1 uM | 24 hrs | Inhibition of aurora B autophosphorylation in human HeLa cells at 1 uM after 24 hrs by Western blotting | 20684549 |
HCT116 | Growth Inhibition Assay | EC50=11±3.3 nM | 21245090 | ||
SW620 | Growth Inhibition Assay | EC50=10±2.1 nM | 21245090 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) 是一種高度選擇性的Aurora B抑制劑,無細胞試驗中IC50為0.37 nM,作用于Aurora B比作用于Aurora A選擇性高3700倍左右。 | ||
---|---|---|---|
靶點 |
|
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT02579226 | Completed | Advanced Solid Tumours |
AstraZeneca |
October 28 2015 | Phase 1 |
分子量 | 507.56 | 分子式 | C26H30FN7O3 |
CAS號 | 722544-51-6 | SDF | Download Barasertib (AZD1152-HQPA) SDF |
Smiles | CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 100 mg/mL ( (197.02 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)
回答:
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.